Medication info
Telmitwin Tablets 40/10 mg

Telmitwin Tablets 40/10 mg

Prescription medicationOral
Ingredient · strength
Telmisartan Powder 23.9%›167.36mg / 1 tabletAmlodipine Besylate›13.87mg / 1 tablet
Manufacturer / importer
(Ltd.) Hanpung Pharmaceutical
Appearance
A biconvex oval double tablet that is white and light gray.
Packaging
30 tablets/PTP [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 201905315 · Approved 2019.07.26 · Insurance code 658106770

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as described below, switching directly to this medicine may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. ○ Patients with renal impairment: Dose adjustment is not necessary in patients with mild or moderate renal impairment. However, in patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: The usual amlodipine regimen is recommended for elderly patients, but caution should be exercised when increasing the dose (see section ‘3. Patients requiring careful administration’). In elderly patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually.
Child dose
○ Pediatric patients: The safety and efficacy of this drug have not been established in pediatric patients 18 years of age or younger; therefore, its use is not recommended.

Ingredients

Manufacturer
(Ltd.) Hanpung Pharmaceutical

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication effectively lowers blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled with monotherapy of amlodipine or telmisartan. Managing essential hypertension is crucial for preventing cardiovascular diseases, and this medication helps stabilize blood pressure. It acts by combining two components that dilate blood vessels and reduce blood pressure, making it suitable for patients with poorly controlled blood pressure. It plays an important role in improving overall cardiovascular health and aids in blood pressure management.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as described below, switching directly to this medicine may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. ○ Patients with renal impairment: Dose adjustment is not necessary in patients with mild or moderate renal impairment. However, in patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: The usual amlodipine regimen is recommended for elderly patients, but caution should be exercised when increasing the dose (see section ‘3. Patients requiring careful administration’). In elderly patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually.

Child dose

○ Pediatric patients: The safety and efficacy of this drug have not been established in pediatric patients 18 years of age or younger; therefore, its use is not recommended.

Precautions

This medication should not be used during pregnancy, particularly in the second and third trimesters, as it can cause serious harm to the fetus. If pregnancy is confirmed, the use of this medication must be discontinued immediately. Patients with hypersensitivity to this medication or with specific heart, liver, or kidney diseases should not take it. It is also advisable for nursing mothers to avoid using this medication. Patients with severe liver disease or heart problems should use this medication cautiously and may require dose adjustments. It should not be administered to patients with significantly low blood pressure or in shock. Caution is needed for patients with diabetes or severe kidney impairment, especially when combined with other medications. Side effects such as dizziness and peripheral edema may occur during treatment, so caution is necessary. Due to the blood pressure-lowering effects, patients should be careful when driving or operating machinery as drowsiness or dizziness may occur. There is a risk of hyperkalemia, so periodic monitoring of potassium levels is recommended. Co-administration with other antihypertensives may result in hypotension or changes in kidney function, thus following the physician's instructions is essential. It is recommended to avoid taking this medication with grapefruit juice as it may enhance the drug's effects. In case of overdose, severe hypotension or heart problems can occur, so the dosage must be strictly adhered to. Special caution is necessary when administering this medication to children or elderly patients; for elderly patients, the dosage should be adjusted slowly. Store this medication in a place out of reach of children, and it is advisable to take it immediately after opening.

Side effects

  • Dizziness
  • peripheral edema
  • syncope
  • upper respiratory infection
  • urinary tract infection
  • cystitis
  • sepsis
  • anemia
  • thrombocytopenia
  • eosinophilia
Show 95 more
  • leukopenia
  • hypersensitivity
  • anaphylactic reaction
  • hyperkalemia
  • hypoglycemia
  • hyponatremia
  • hyperglycemia
  • depression
  • insomnia
  • anxiety
  • confusion
  • drowsiness
  • headache
  • migraine
  • paresthesia
  • hypoesthesia
  • dysgeusia
  • tremor
  • extrapyramidal disorder
  • muscular rigidity
  • visual impairment
  • vertigo
  • tinnitus
  • palpitations
  • bradycardia
  • tachycardia
  • myocardial infarction
  • ventricular tachycardia
  • arrhythmia
  • atrial fibrillation
  • flushing
  • hypotension
  • orthostatic hypotension
  • vasculitis
  • cough
  • dyspnea
  • rhinitis
  • change in bowel habits
  • abdominal pain
  • dyspepsia
  • nausea
  • vomiting
  • dry mouth
  • gingival hyperplasia
  • pancreatitis
  • gastritis
  • liver dysfunction
  • liver disorder
  • hepatitis
  • jaundice
  • increased liver enzymes
  • pruritus
  • sweating
  • rash
  • hair loss
  • purpura
  • skin discoloration
  • eczema
  • erythema
  • angioedema
  • toxic skin eruption
  • drug rash
  • urticaria
  • erythema multiforme
  • exfoliative dermatitis
  • Stevens-Johnson syndrome
  • photosensitivity reaction
  • toxic epidermal necrolysis
  • joint swelling
  • muscle cramps
  • arthralgia
  • myalgia
  • back pain
  • limb pain
  • tendon pain
  • renal impairment
  • urinary disorders
  • polyuria
  • nocturia
  • erectile dysfunction
  • gynecomastia
  • edema
  • asthenia
  • fatigue
  • chest pain
  • malaise
  • influenza-like illness
  • increased liver enzymes
  • increased blood creatinine
  • weight gain
  • weight loss
  • increased blood uric acid
  • increased blood creatine phosphokinase
  • decreased hemoglobin
  • intestinal vascular edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a tightly sealed container that blocks light. It is crucial to maintain a storage temperature between 1°C and 30°C in order to preserve the drug's effectiveness and safety.

Appearance and packaging

Appearance

A biconvex oval double tablet that is white and light gray.

Package unit

30 tablets/PTP [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.